Albemarle stock declined 2.84% to $95.39, outpacing the broader market's 1.09% loss. The specialty chemicals company has lost 14.66% over the past month, significantly underperforming the S&P 500's 2.44% gain.
Upcoming earnings on November 4, 2026 are expected to show strong growth with EPS projected at $2.44 (up 1384.21% YoY) and revenue of $1.49 billion (up 14.15% YoY). However, the stock carries a Zacks Rank #3 (Hold) rating with a recent 0.83% downward revision in consensus EPS estimates.